Literature DB >> 11531253

Analysis of the TGF beta functional pathway in epithelial ovarian carcinoma.

K M Francis-Thickpenny1, D M Richardson, C C van Ee, D R Love, I M Winship, B C Baguley, G Chenevix-Trench, A N Shelling.   

Abstract

Epithelial ovarian carcinoma is often diagnosed at an advanced stage of disease and is the leading cause of death from gynaecological neoplasia. The genetic changes that occur during the development of this carcinoma are poorly understood. It has been proposed that IGFIIR, TGFbeta1 and TGFbetaRII act as a functional unit in the TGFbeta growth inhibitory pathway, and that somatic loss-of-function mutations in any one of these genes could lead to disruption of the pathway and subsequent loss of cell cycle control. We have examined these 3 genes in 25 epithelial ovarian carcinomas using single-stranded conformational polymorphism analysis and DNA sequence analysis. A total of 3 somatic missense mutations were found in the TGFbetaRII gene, but none in IGFRII or TGFbeta1. An association was found between TGFbetaRII mutations and histology, with 2 out of 3 clear cell carcinomas having TGFbetaRII mutations. This data supports other evidence from mutational analysis of the PTEN and beta-catenin genes that there are distinct developmental pathways responsible for the progression of different epithelial ovarian cancer histologic subtypes. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11531253      PMCID: PMC2364123          DOI: 10.1054/bjoc.2001.1950

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  32 in total

Review 1.  Structural framework for the protein kinase family.

Authors:  S S Taylor; D R Knighton; J Zheng; L F Ten Eyck; J M Sowadski
Journal:  Annu Rev Cell Biol       Date:  1992

2.  Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus.

Authors:  G Chenevix-Trench; J Leary; J Kerr; J Michel; R Kefford; T Hurst; P G Parsons; M Friedlander; S K Khoo
Journal:  Oncogene       Date:  1992-06       Impact factor: 9.867

3.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.

Authors:  M Orita; H Iwahana; H Kanazawa; K Hayashi; T Sekiya
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines.

Authors:  J N Rich; M Zhang; M B Datto; D D Bigner; X F Wang
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

5.  Molecular genetic analysis of TGF-beta1 in ovarian neoplasia.

Authors:  M R Cardillo; E Yap; G Castagna
Journal:  J Exp Clin Cancer Res       Date:  1997-03

6.  Molecular genetic analysis of TGF beta1 in breast cancer.

Authors:  M R Cardillo; E Yap; G Castagna
Journal:  J Exp Clin Cancer Res       Date:  1997-03

7.  Atomic structure of the MAP kinase ERK2 at 2.3 A resolution.

Authors:  F Zhang; A Strand; D Robbins; M H Cobb; E J Goldsmith
Journal:  Nature       Date:  1994-02-24       Impact factor: 49.962

Review 8.  Latent transforming growth factor-beta: structural features and mechanisms of activation.

Authors:  J S Munger; J G Harpel; P E Gleizes; R Mazzieri; I Nunes; D B Rifkin
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

9.  Two different signal transduction pathways can be activated by transforming growth factor beta 1 in epithelial cells.

Authors:  Z Yan; S Winawer; E Friedman
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

Review 10.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

View more
  12 in total

Review 1.  Reversal of tumor-induced immunosuppression by TGF-beta inhibitors.

Authors:  Slawomir Wojtowicz-Praga
Journal:  Invest New Drugs       Date:  2003-02       Impact factor: 3.850

Review 2.  Molecular pathogenesis of endometrial and ovarian cancer.

Authors:  Melissa A Merritt; Daniel W Cramer
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Epigenetic suppression of the TGF-beta pathway revealed by transcriptome profiling in ovarian cancer.

Authors:  Noriomi Matsumura; Zhiqing Huang; Seiichi Mori; Tsukasa Baba; Shingo Fujii; Ikuo Konishi; Edwin S Iversen; Andrew Berchuck; Susan K Murphy
Journal:  Genome Res       Date:  2010-12-14       Impact factor: 9.043

Review 4.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

5.  In situ detection of TGF betas, TGF beta receptor II mRNA and telomerase activity in rat cholangiocarcinogenesis.

Authors:  Jian-Ping Lu; Jian-Qun Mao; Ming-Sheng Li; Shi-Lun Lu; Xi-Qi Hu; Shi-Neng Zhu; Shintaro Nomura
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

Review 6.  Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.

Authors:  Robert J Kurman; Kala Visvanathan; Richard Roden; T C Wu; Ie-Ming Shih
Journal:  Am J Obstet Gynecol       Date:  2008-04       Impact factor: 8.661

7.  Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-β cytostatic program and blocks the antiproliferative effect of TGF-β.

Authors:  B Q Trinh; N Barengo; H Naora
Journal:  Oncogene       Date:  2011-02-07       Impact factor: 9.867

Review 8.  Ovarian cancer biomarker discovery based on genomic approaches.

Authors:  Jung-Yun Lee; Hee Seung Kim; Dong Hoon Suh; Mi-Kyung Kim; Hyun Hoon Chung; Yong-Sang Song
Journal:  J Cancer Prev       Date:  2013-12

Review 9.  Quercetin and ovarian cancer: An evaluation based on a systematic review.

Authors:  Arefe Parvaresh; Roghaye Razavi; Nahid Rafie; Reza Ghiasvand; Makan Pourmasoumi; Maryam Miraghajani
Journal:  J Res Med Sci       Date:  2016-05-09       Impact factor: 1.852

10.  Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro.

Authors:  Hong Liu; Guonan Zhang; Jianming Huang; Shiqi Ma; Kun Mi; Jia Cheng; Yi Zhu; Xiao Zha; Wei Huang
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.